Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Patients with HER2-negative advanced breast cancer have limited choice on targeted
therapies, and often show only modest responses to available immunotherapies. Adoptive cell
therapy with tumor-infiltrating lymphocytes has difficulties in preparing enough cells from
solid tumors and overcoming the exhaustion and dysfunction of T cells, which limit its
clinical use. Tumor-draining lymph node-derived lymphocytes (LNLs) that have abundant
tumor-specific T cells, rather than exhausted T cells, are easier to produce. It is not yet
known whether LNL treatment is safe and effective in patients with advanced HER2-negative
breast cancer.
PURPOSE: This phase I trial is mainly to study the safety of autologous LNL in patients with
advanced HER2-negative breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University